A new biotech business model aimed at earning faster returns for investors will be facing its first test in the next 12 months.
Seattle-based biotech Kineta is taking a nontraditional approach, essentially hoping to make a profit more quickly by licensing its drug discoveries without investing heavily in production.
“It doesn’t have to take forever to develop a drug,” said Charles Magness, president and CEO of Kineta. “It doesn’t have to cost $1.5 billion.”
The traditional model for…
A new biotech business model aimed at earning faster returns for investors will be facing its first test in the next 12 months.
Seattle-based biotech Kineta is taking a nontraditional approach, essentially hoping to make a profit more quickly by licensing its drug discoveries without investing heavily in production.
“It doesn’t have to take forever to develop a drug,” said Charles Magness, president and CEO of Kineta. “It doesn’t have to cost $1.5 billion.”
The traditional model for…